PDF(Pubmed)
Abstract：
Dysarthria is a common and debilitating symptom of many neurodegenerative diseases, including those resulting in ataxia. Changes to speech lead to significant reductions in quality of life, impacting the speaker in most daily activities. Recognition of its importance as an objective outcome measure in clinical trials for ataxia is growing. Its viability as an endpoint across the disease spectrum (i.e. pre-symptomatic onwards) means that trials can recruit ambulant individuals and later-stage individuals who are often excluded because of difficulty completing lower limb tasks. Here we discuss the key considerations for speech testing in clinical trials including hardware selection, suitability of tasks and their role in protocols for trials and propose a core set of tasks for speech testing in clinical trials. Test batteries could include forms suitable for remote short, sensitive and easy to use, with norms available in several languages. The use of artificial intelligence also could improve accuracy and automaticity of analytical pipelines in clinic and trials.
摘要：
构音障碍是许多神经退行性疾病的常见和衰弱的症状，包括那些导致共济失调的。语言的改变导致生活质量显著下降，在大多数日常活动中影响演讲者。在共济失调的临床试验中，人们越来越认识到其作为客观结果指标的重要性。它作为整个疾病谱的终点（即症状前开始）的可行性意味着试验可以招募因难以完成下肢任务而经常被排除在外的门诊个体和后期个体。在这里，我们讨论了临床试验中语音测试的关键考虑因素，包括硬件选择，任务的适用性及其在试验方案中的作用，并提出了一组用于临床试验中语音测试的核心任务。测试电池可以包括适合远程短路的形式，敏感和易于使用，有几种语言的规范。人工智能的使用还可以提高临床和试验中分析管道的准确性和自动化程度。
